Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-824393 in Chronic Hepatitis C Virus Genotype 1
NCT01142700Phase 2Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2010
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BMS-824393 in hepatitis C virus infection (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Serious Adverse Events and Discontinuations due to Adverse Events at 48 weeks and Extended Rapid Virologic Response at 12 weeks. Planned start Jul 2010; status: withdrawn.
02
Drugs
BMS-824393
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT01142700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01142700.